PE20080609A1 - Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano como moduladores de d3 - Google Patents
Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano como moduladores de d3Info
- Publication number
- PE20080609A1 PE20080609A1 PE2007001117A PE2007001117A PE20080609A1 PE 20080609 A1 PE20080609 A1 PE 20080609A1 PE 2007001117 A PE2007001117 A PE 2007001117A PE 2007001117 A PE2007001117 A PE 2007001117A PE 20080609 A1 PE20080609 A1 PE 20080609A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- oxazol
- triazol
- thio
- fluoro
- Prior art date
Links
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 title abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title abstract 3
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical class F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 abstract 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 abstract 1
- -1 TARTRATE COMPOUND Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2006/008314 WO2007022980A1 (en) | 2005-08-22 | 2006-08-21 | Use of azabicyclo hexane derivatives |
| GBGB0616574.0A GB0616574D0 (en) | 2006-08-21 | 2006-08-21 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080609A1 true PE20080609A1 (es) | 2008-07-26 |
Family
ID=37081324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001117A PE20080609A1 (es) | 2006-08-21 | 2007-08-17 | Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano como moduladores de d3 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20080058398A1 (enExample) |
| EP (1) | EP2054054A1 (enExample) |
| JP (1) | JP5315244B2 (enExample) |
| KR (1) | KR101495362B1 (enExample) |
| CN (1) | CN101528221B (enExample) |
| AR (1) | AR062471A1 (enExample) |
| AU (1) | AU2007287527B2 (enExample) |
| BR (1) | BRPI0716454A2 (enExample) |
| CA (1) | CA2661437A1 (enExample) |
| CL (1) | CL2007002422A1 (enExample) |
| CO (1) | CO6150139A2 (enExample) |
| CR (1) | CR10638A (enExample) |
| EA (1) | EA017917B1 (enExample) |
| GB (1) | GB0616574D0 (enExample) |
| IL (1) | IL196976A0 (enExample) |
| MA (1) | MA30672B1 (enExample) |
| MX (1) | MX2009001941A (enExample) |
| NO (1) | NO20090834L (enExample) |
| PE (1) | PE20080609A1 (enExample) |
| TW (1) | TW200825074A (enExample) |
| WO (1) | WO2008022994A1 (enExample) |
| ZA (1) | ZA200900886B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005080382A1 (en) * | 2004-02-23 | 2005-09-01 | Glaxo Group Limited | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors |
| GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| US7807698B2 (en) * | 2005-06-14 | 2010-10-05 | Glaxo Group Limited | Azabicyclo[3.1.0]hexane derivatives as modulators of the dopamine D3 receptor |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| WO2007022933A1 (en) * | 2005-08-22 | 2007-03-01 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine d3 receptors |
| GB0517175D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| US8163927B2 (en) * | 2006-04-03 | 2012-04-24 | Glaxo Group Limited | Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors |
| US8222266B2 (en) * | 2006-04-03 | 2012-07-17 | Glaxo Group Limited | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors |
| EP2167083B1 (en) * | 2007-06-06 | 2015-10-28 | Euthymics Bioscience, Inc. | 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| TW202444703A (zh) | 2021-09-14 | 2024-11-16 | 美商美國禮來大藥廠 | Sstr4促效劑鹽 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4260941B2 (ja) * | 1998-11-09 | 2009-04-30 | 株式会社片山製薬所 | アゼチジン−３−オール |
| JP2002539194A (ja) * | 1999-03-15 | 2002-11-19 | ノボ ノルディスク アクティーゼルスカブ | 新規の（２ｒ，３ｒ，４ｒ）−３，４−ジヒドロキシ−２−ヒドロキシメチルピロリジンの塩 |
| GB0019228D0 (en) * | 2000-08-04 | 2000-09-27 | Smithkline Beecham Plc | Novel pharmaceutical |
| WO2005080382A1 (en) * | 2004-02-23 | 2005-09-01 | Glaxo Group Limited | Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors |
| SE526837C2 (sv) * | 2004-02-24 | 2005-11-08 | Kongsberg Automotive Asa | Växelspakstransmission |
| US20070249623A1 (en) * | 2004-06-30 | 2007-10-25 | Eli Lilly And Company Patent Division | 1-(Indole-6-Carbonyl-D-Phenylglycinyl)-4-(1-Methylpiperidin-4-Yl)Piperazine D-Tartrate |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
-
2006
- 2006-08-21 GB GBGB0616574.0A patent/GB0616574D0/en not_active Ceased
-
2007
- 2007-08-17 PE PE2007001117A patent/PE20080609A1/es not_active Application Discontinuation
- 2007-08-20 AU AU2007287527A patent/AU2007287527B2/en not_active Ceased
- 2007-08-20 EP EP07788490A patent/EP2054054A1/en not_active Withdrawn
- 2007-08-20 MX MX2009001941A patent/MX2009001941A/es active IP Right Grant
- 2007-08-20 EA EA200970211A patent/EA017917B1/ru not_active IP Right Cessation
- 2007-08-20 BR BRPI0716454-8A2A patent/BRPI0716454A2/pt not_active IP Right Cessation
- 2007-08-20 JP JP2009525046A patent/JP5315244B2/ja not_active Expired - Fee Related
- 2007-08-20 CA CA002661437A patent/CA2661437A1/en not_active Abandoned
- 2007-08-20 CL CL200702422A patent/CL2007002422A1/es unknown
- 2007-08-20 TW TW096130644A patent/TW200825074A/zh unknown
- 2007-08-20 US US11/841,015 patent/US20080058398A1/en not_active Abandoned
- 2007-08-20 CN CN2007800392082A patent/CN101528221B/zh not_active Expired - Fee Related
- 2007-08-20 KR KR1020097003484A patent/KR101495362B1/ko not_active Expired - Fee Related
- 2007-08-20 WO PCT/EP2007/058636 patent/WO2008022994A1/en not_active Ceased
- 2007-08-21 AR ARP070103715A patent/AR062471A1/es not_active Application Discontinuation
-
2009
- 2009-02-06 ZA ZA2009/00886A patent/ZA200900886B/en unknown
- 2009-02-09 IL IL196976A patent/IL196976A0/en unknown
- 2009-02-20 CO CO09017330A patent/CO6150139A2/es unknown
- 2009-02-23 NO NO20090834A patent/NO20090834L/no not_active Application Discontinuation
- 2009-02-25 CR CR10638A patent/CR10638A/es not_active Application Discontinuation
- 2009-02-27 MA MA31673A patent/MA30672B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007287527A1 (en) | 2008-02-28 |
| JP5315244B2 (ja) | 2013-10-16 |
| EA200970211A1 (ru) | 2009-08-28 |
| MA30672B1 (fr) | 2009-08-03 |
| GB0616574D0 (en) | 2006-09-27 |
| CL2007002422A1 (es) | 2008-03-14 |
| AU2007287527B2 (en) | 2013-01-31 |
| KR101495362B1 (ko) | 2015-02-24 |
| US20080058398A1 (en) | 2008-03-06 |
| AR062471A1 (es) | 2008-11-12 |
| NO20090834L (no) | 2009-03-19 |
| CN101528221B (zh) | 2013-05-08 |
| WO2008022994A1 (en) | 2008-02-28 |
| ZA200900886B (en) | 2011-05-25 |
| CN101528221A (zh) | 2009-09-09 |
| KR20090052327A (ko) | 2009-05-25 |
| BRPI0716454A2 (pt) | 2014-03-04 |
| CA2661437A1 (en) | 2008-02-28 |
| JP2010501519A (ja) | 2010-01-21 |
| CR10638A (es) | 2009-03-20 |
| TW200825074A (en) | 2008-06-16 |
| MX2009001941A (es) | 2009-03-05 |
| IL196976A0 (en) | 2009-11-18 |
| EA017917B1 (ru) | 2013-04-30 |
| EP2054054A1 (en) | 2009-05-06 |
| CO6150139A2 (es) | 2010-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080609A1 (es) | Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4h-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano como moduladores de d3 | |
| CL2011002697A1 (es) | Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes | |
| PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
| PE20051173A1 (es) | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 | |
| EA200901157A1 (ru) | Конденсированные кольцевые гетероциклические модуляторы киназы | |
| CL2007002167A1 (es) | Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer. | |
| EA201100978A1 (ru) | Схема приема агониста рецептора s1p | |
| CL2008002199A1 (es) | Compuestos derivados de 1,3-oxazin-2-ona; composicion farmaceutica que comprende a dichos compuestos; y uso para tratar una enfermedad asociada con la actividad de la 11beta-hidroxiesteroide deshidrogenasa tipo 1 (11beta-hsd1) tales como dislipidemia, hiperlipidemia, hipertension, obesidad y enfermedad cardiovascular, entre otras. | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| EA201692167A1 (ru) | Модуляторы толл-подобных рецепторов | |
| CO6531458A2 (es) | Nuevos compuestos de espiropiperidina | |
| EA201290103A1 (ru) | Гетероциклические соединения и их использование | |
| PE20140252A1 (es) | ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropidin-4-il)etoxi)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino como inhibidor de fgrf | |
| PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
| PT2040755E (pt) | Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6 | |
| CR10748A (es) | Compuesto de indol | |
| EA201100161A1 (ru) | Производные хинуклидина карбоната и их медицинские композиции | |
| DOP2012000139A (es) | Nuevos compuestos de espiropiperidina | |
| EA200970018A1 (ru) | 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазин в качестве соединения с сочетанием активности в отношении повторного захвата серотонина, 5-нт3 и 5-нт1а для лечения когнитивного нарушения | |
| EA201391662A1 (ru) | Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2 | |
| CL2013000768A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de (6s)-6-(2-hidroxi-2-metilpropil)-6-fenil-3-{(1s)-1-[4-(2-oxo-1,2-dihidropiridin-4-il)fenil]etil}-1,3-oxazin-2-ona y un segundo agente terapéutico; y su uso para prevenir o retrasar un trastorno asociado a diabetes mellitus 2 o tolerancia alterada a la glucosa. | |
| EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
| PE20100050A1 (es) | Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona | |
| EA201171339A1 (ru) | Способ снижения внутриглазного давления у людей | |
| UY32069A (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-triifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |